Dr Andreeff on the Rationale for Investigating Uproleselan Plus Venetoclax and Azacitidine in AML
Michael Andreeff, MD, PhD, discusses the rationale for investigating uproleselan plus venetoclax and azacitidine in patients with acute myeloid leukemia.
Source: onclive.com